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Abstract  
Background: Cocaine dependence has been associated with blunted dopamine and norepinephrine 
signaling but it is unknown if also recreational cocaine use is associated with alterations of 
catecholamine systems. Prepulse inhibition (PPI) of the acoustic startle response (ASR) – a measure of 
sensorimotor gating – is highly sensitive for manipulations of the catecholamine systems. Therefore, 
we investigated whether relatively pure recreational (RCU) and dependent cocaine users (DCU) 
display alterations of PPI, startle reactivity, and habituation. Moreover, the influences of MDMA and 
cannabis co-use, craving, and Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms on startle 
measures were examined. 
Methods: In 64 RCU, 29 DCU, and 66 stimulant-naïve controls PPI of ASR, startle reactivity, 
habituation, ADHD symptoms, and cocaine craving were assessed. Drug use of all participants was 
controlled by hair and urine toxicologies. 
Results: Both, RCU and DCU showed increased PPI in comparison to control participants (Cohen’s 
d=.38, d=.67, respectively), while RCU and DCU did not differ in PPI measures (d=.12). No 
significant group differences were found in startle reactivity or habituation measures. In cocaine users, 
PPI was positively correlated with cumulative cocaine dose used, craving for cocaine, and ADHD 
symptoms. Users with a diagnosis of ADHD and strong craving symptoms displayed the highest PPI 
levels compared to controls (d=.78). 
Conclusion: The augmented PPI in RCU and DCU suggests that already recreational use of cocaine is 
associated with altered catecholamine signaling in particular if ADHD or craving symptoms are 
present. Finally, ADHD might be a critical risk factor for cocaine-induced changes of the 
catecholamine system. 
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Introduction  
Cocaine is an illegal drug with a high tendency to induce dependence when chronically abused (1). 
Nevertheless, a substantial part of people use cocaine in a recreational and non-dependent manner (2). 
The lifetime prevalence of cocaine use is estimated at 5.9% amongst 15-34 year olds in Europe. It has 
been established as the most commonly stimulant drug used in Europe (2) and is the primary stimulant 
drug responsible for drug-dependence treatment in North and South America (3). 
Cocaine inhibits the reuptake of dopamine (DA), norepinephrine (NE), and serotonin (4). Marked 
structural and functional alterations in striatal and prefrontal regions have been reported in dependent 
cocaine users (DCU)(5-9). Furthermore, reduced striatal DA D2 receptor availability and blunted 
striatal DA release have repeatedly been shown to be associated with chronic cocaine use in humans 
using PET imaging (10-13). Striatal DA is a central mediator of reward, memory, and behavioral 
inhibition (14). Thus, dysregulated DA functioning in DCU has been associated with widespread 
consequences including craving, impulsive behavior, loss of control over drug intake, and relapse 
(12,13,15). Recently, also upregulation of thalamic NE transporters has been reported in DCU (16) 
and NE seems to play an important role in craving, withdrawal-related anxiety, and relapse in cocaine 
addiction (17,18). While most studies investigated dependent users, little is known about the effects of 
occasional and recreational cocaine use. However, a recent study showing blue-yellow color vision 
deficits in recreational cocaine users (RCU) and DCU suggests that already recreational cocaine use 
might lead to changes in DA function (19). 
 
Prepulse inhibition (PPI) of the acoustic startle response (ASR) refers to the attenuation of the 
reflexive startle reaction when the startling stimulus is preceded 30-500ms by a weak and non-startling 
stimulus (20). PPI is considered as a translational measure of sensorimotor gating, reflecting a 
universal pre-attentional filter function (21) that is regulated by a cortico-striato-pallido-pontine 
(CSPP) circuit involving the prefrontal cortex, the ventral striatum including NAcc, the ventral 
pallidum, and the pontine tegmentum (22). PPI has been shown to be highly sensitive to changes in 
catecholamine neurotransmission, especially in the ventral part of the mesostriatal DA system (23,24), 
and in thalamocortical and ventral forebrain NE networks (25-28). 
Acute administration of cocaine reduced PPI in rats (29), but lasting effects of repeated drug exposure 
are less well studied. In cocaine-withdrawn rats no alterations in PPI were found (29,30). In humans, 
Efferen et al.(31) reported a trend towards increased PPI in a small sample of DCU (n=10 vs. n=9 
4    K. H. Preller, et al. 
controls). In this study, DCU displayed reduced startle reactivity (31), while a subsequent study 
revealed that decreased startle was only present in DCU with continued abstinence (>40 days) (32). 
With regard to startle reactivity, animal results are inconsistent. Adams et al.(30) showed reduced 
startle reactivity in cocaine-withdrawn rats, whereas Martinez et al.(29) found no significant 
differences in startle reactivity or habituation. However, PPI has not been studied in a sufficiently 
large sample of cocaine users so far. Moreover, the effects of recreational cocaine use on PPI and 
startle reactivity are unknown. The overlap of reward circuits shown to be altered in cocaine users (in 
particular the ventral striatum) and CSPP circuits regulating PPI suggests that PPI may be altered in 
cocaine addiction (9,10,22,23). 
 
Therefore, we aimed to investigate startle reactivity and PPI in large groups of RCU and DCU, and 
stimulant-naïve control subjects. Preliminary data from a previous study predict increased PPI levels 
and decreased ASR in DCU (31), while we expect to find a similar but less pronounced pattern already 
in RCU (19). Given that Attention-Deficit/Hyperactivity Disorder (ADHD) is highly comorbid with 
cocaine dependence and abuse (33) and it was shown that ADHD patients also display alterations in 
DA and NE signaling (34,35), we additionally assessed the severity of ADHD symptoms in our 
subjects. Moreover, we examined the severity of cocaine craving, as craving was associated with low 
striatal DA levels and NE alterations as well (12,36). Psychiatric comorbidities, such as ADHD, and 
polytoxic drug use have been shown to be confounded in studies especially with DCU (37,38). We 
aimed to overcome these previous limitations I) by the inclusion of a group of recreational and 
presumably less comorbid and polytoxic users, II) by controlling ADHD symptoms, and III) by the 
application of comprehensive psychiatric diagnostics and the examination of hair toxicologies 
allowing the exclusion of subjects with psychiatric diseases (other than substance dependence or 
ADHD) and polytoxic drug use patterns. 
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Methods 
Participants 
Twenty-nine DCU, 64 RCU, and 66 drug-naïve control participants took part in the study (for 
recruitment and selection details see supplemental information). Cocaine dependence was diagnosed 
following the Diagnostic and Statistical Manual-IV (DSM-IV) criteria (39), with DCU fulfilling these 
criteria and RCU not meeting dependency criteria. Further inclusion criteria for the two user groups 
were cocaine use of at least 1g/month, cocaine as primary used illegal drug, and a current abstinence 
duration <6 months. Participants had to be aged between 18 and 60 years. Exclusion criteria for the 
user groups were use of opioids, a polytoxic drug use pattern, and an Axis-I DSM-IV adult psychiatric 
disorder with exception of cocaine and alcohol abuse/dependence, a history of a depression (acute 
major depression was excluded), and ADHD. Control subjects were excluded when they displayed any 
Axis-I DSM-IV psychiatric disorder inclusive ADHD and any form of addiction or regular illegal drug 
use (lifetime use <15 occasions) with exception of cannabis. Exclusion criteria for all participants 
were a neurological disorder or head injury, clinically relevant medical diseases, family history of 
schizophrenia or bipolar disorder, or prescription drugs affecting the CNS, and medical conditions 
concerning eyes, ears, and equilibrium organs. All participants had to abstain from illegal substances 
for a minimum of three days and from alcohol for at least 24h. Self-reports were controlled by urine 
and 6-month hair analysis (details see supplemental information). 
The study was approved by the Cantonal Ethics Committee of Zurich (KEK). All participants 
provided written informed-consent and were compensated for their participation. 
 
Procedure 
The present data were collected as part of a larger longitudinal study on socio-cognitive consequences 
of cocaine use – the Zurich Cocaine Cognition Study (ZuCo2St). A Structured Clinical Interview for 
DSM-IV Disorders (SCID-I) was carried out by a trained psychologist. Drug use was assessed by 
means of the Interview for Psychotropic Drug Consumption (40). The brief version of the Cocaine 
Craving Questionnaire (CCQ)(41) was applied to assess current cocaine craving. The Fagerström Test 
of Nicotine Dependence (FTND)(42) was used to assess the level of nicotine dependency. The 
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Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B)(43), a standardized German vocabulary test, was 
carried out for the estimation of premorbid verbal intelligence quotient (IQ). The Beck Depression 
Inventory (BDI)(44) measured the current severity of depressive symptoms, and the ADHD self-rating 
scale (ADHD-SR)(45) was applied to allow for the diagnosis of ADHD in adulthood according to 
DSM-IV criteria. A neuropsychological test battery was assessed (data will be published elsewhere) 
and subsequently the ASR measurement was conducted. Participants had to abstain from smoking for 
at least 60min prior to startle testing.  
 
Startle Response Measurement 
For a detailed description of the paradigm, see supplemental information. In brief, startle stimuli 
comprised of noise bursts at an 115dB sound pressure level with duration of 40ms, separated by 
variable inter-trial-intervals (range: 9-14 seconds, mean: 12 seconds). After an initial pulse-alone trial 
(PA) the session included a total of 64 trials (56 active and 8 no-stimulation trials). Thirty-two pulse 
trials were preceded by a 20ms prepulse with an intensity of 86dB and a stimulus onset asynchrony 
(SOA) of 30, 60, 120, and 240ms, resulting in four SOA conditions. The eye-blink component of the 
ASR was measured by an EMG startle system (EMG-SR-Lab; San Diego Instruments, USA) as 
described previously (21). Preprocessing of the recorded data was performed using Analyzer software 
(Brainvision, Germany) and emgBLINK version 1.2 (CST, Switzerland) as described in detail 
previously (46).  
 
Statistical Analysis 
Frequency data were analyzed by means of Pearson’s Chi-square test and quantitative data by analyses 
of variance (ANOVA) using PASW 18.0 (IBM, Switzerland). PPI and habituation data were normally 
distributed in each group (Kolmogorov- Smirnov test p>.05) and were therefore analyzed 
parametrically. The mean %PPI was calculated for each SOA as described prevously (21,47). These 
data were analyzed using mixed-design analyses of covariance (ANCOVA) with Greenhouse-Geisser 
corrections, followed by Sidak-corrected pair-wise comparisons and simple main effects analyses. 
SOA condition was introduced as within-subjects factor and group as between-subjects factor. As 
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smoking status, sex (3-fold: women differentiated by luteal vs. follicular phase of the menstrual cycle), 
and age were shown to influence startle parameters (48-52), these variables were introduced as 
covariates.  
Startle reactivity measures were analyzed likewise. To assess habituation, PA trials of block 1-4 were 
analyzed conducting a mixed-design ANCOVA (53). Percent habituation was calculated as the 
reduction in startle magnitude between the second block and following blocks of PA trials 
(%Habituation=100*(block 2–block n)/block 2) to avoid sensitization effects (27). Furthermore, the 
linear gradient coefficient b was calculated across the four blocks of PA as described previously (47). 
%Habituation and b were analyzed by one-way ANCOVAs controlling for smoking status, sex, and 
age.  
Correlation analyses (Pearson’s product-moment) were conducted to relate drug use parameters to PPI 
measures. Cumulated cocaine lifetime use was ln-transformed for statistical analyses because of the 
highly skewed distribution and the resulting deviation from the normal distribution (Shapiro-Wilk 
W<.001 for both user groups). For correlations between illegal drug use and PPI control subjects were 
excluded to prevent inflating existing correlations. The confirmatory statistical comparisons of all data 
were carried out on a significance level set at p<.05 (two-tailed).  
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Results 
Demographic characteristics 
The groups did not differ with respect to IQ, sex distribution, and proportion of smokers and non-
smokers (Table 1). DCU were older than controls and RCU (p<.05) and had fewer years of education 
than controls (p<.05). As expected, both user groups scored higher on the BDI and ADHD-SR sum 
scores compared to controls (all p<.01). FTND sum score differed between the smokers in each group 
(p<.05-.01). The hair samples revealed a clear dominance of cocaine compared to other illegal drugs 
as strived for by the inclusion criteria (Table 2). DCU showed a more than 7-fold higher concentration 
of cocaine and metabolites in the hair samples compared to RCU. However, RCU are regular users 
with a mean weekly consumption of about 1g cocaine but without fulfilling DSM-IV criteria for 
cocaine dependence. A considerable amount of participants tested positive in urine toxicologies for 
cocaine and cannabis and we decided not to exclude them but to investigate the acute and post-acute 
effects of the drugs. 
 
PPI 
A mixed effects ANCOVA (SOA*group) revealed a significant main effect for SOA (F(3,459)=9.50, 
p<.001) and a significant between subjects effect for group (F(2,153)=4.58, p<.01)(Figure 1). The 
main effect of SOA reflects the nature of PPI to increase with rising SOA (54). The interaction of 
SOA*group was not significant (F(6,459)=.97, p=.44). Sidak-corrected pairwise comparisons showed 
a significantly increased mean %PPI for RCU (p<.05, d=.38) and DCU (p<.05, d=.67) compared to 
controls, whereas RCU and DCU did not differ from each other (p=.94, d=.12). A significant effect 
was found for the covariate sex (F(1,153)=4.95, p<.05) (women in follicular phase and men>women 
in luteal phase), whereas the effects of age (F(1,153)=1.74, p=.19) and smoking status (F(1,153)=.64, 
p=.43) did not reach significance.  
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Startle Reactivity and Habituation 
ANCOVAs performed for groups did not show significant differences in startle reactivity measures 
(all p>.42), although DCU showed slightly decreased startle reactivity compared to controls (d=.36, 
d=.43, respectively)(Table 3). Furthermore, no significant differences between groups were found for 
the mean of PPA trials and no-stimulation trials (all p>.53). Running the PPI analysis with and without 
covarying for PA first block yielded similar results. 
A mixed-design ANCOVA (PA trials block 1-4*group, smoking status, sex, age, and startle reactivity 
in block 1 as covariates) did not reveal a significant block*group interaction (F(6,411)=.40, p=.85), 
indicating that habituation did not differ between groups (Figure S1). Furthermore, %habituation did 
not differ between groups across blocks and neither did the linear gradient coefficient b (all 
p>.44)(Table 3). 
 
Correlations with cocaine use parameters 
In cocaine users, %PPI mean across SOA conditions was significantly correlated with cumulated 
cocaine use (ln-transformed)(r=.23, p<.03) and duration of cocaine use (r=.22, p<.03), indicating an 
increasing PPI with growing amount and time of use (Figure S2). The effects remained after adjusting 
for age. Correlations between %PPI mean across conditions and current cocaine use, as well as hair 
samples did not reach significance (p>.28).  
 
Urine toxicology and drug use 
To test the influence of recent cocaine use, cocaine users were divided into users with positive (n=26, 
range: 268–43’219ng/ml, mean: 5’438ng/ml, SD: 10’599ng/ml) and users with negative urine samples 
(n=67) and compared with controls (n=66). A mixed effects ANCOVA (SOA*group) revealed a 
significant between subjects effect for group (F(2,153)=4.83, p<.01). Sidak-corrected pair-wise 
comparisons yielded a significantly increased mean %PPI in users with negative urine samples in 
comparison to controls (p<.01, d=.50). The SOA*group interaction did not reach significance (Figure 
S3). 
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Analogously, the influence of recent cannabis use was investigated by dividing cocaine users into 
users with positive (n=34, range: 60–726ng/ml, mean: 120ng/ml, SD: 139ng/ml) and users with 
negative urine samples for cannabis (n=59). They were compared to controls with positive (n=12, 
range: 66–426ng/ml, mean: 163ng/ml, SD: 131ng/ml) and controls with negative urine samples 
(n=54). A mixed effects ANCOVA (SOA*group) revealed a significant between subjects effect for 
group (F(3,152)=3.33, p<.02). Sidak-corrected pair-wise comparisons yielded still significant 
differences between users with negative urine samples and controls with negative urine samples 
(p<.01, d=.51) regarding mean %PPI (Figure 2). The interaction of SOA*group was not significant 
(F(9,453)=0.62, p>.78).  
An ANCOVA (with age and sex as covariates) of mean %PPI comparing controls and cocaine users 
stratified for smoking status revealed a significant group effect (F(3,153)=4.73, p<.01)(Figure 3). 
Non-smoking controls differed significantly from smoking cocaine users (p<.01, d=.90), while the 
difference to the non-smoking cocaine users was not significant (p<.30) despite the considerable effect 
size (d=.63) due to the small group sizes (n=16 vs. n=19). 
A detailed analysis of the influence of the use of MDMA and cannabis on PPI is presented in the 
supplemental material. 
 
Craving and ADHD 
In cocaine users, CCQ sum score correlated significantly with %PPI mean across conditions (r=.22, 
p<.03). Furthermore, when dividing users in a high and low craving group by median split and 
comparing them with controls (Figure S4), a mixed effects ANCOVA (SOA*group) revealed a 
significant main effect for group (F(2,153)=7.05, p<.001). Sidak-corrected pairwise comparisons 
revealed a significant difference between controls and cocaine users with high craving (p<.001, 
d=.69). Introducing cumulative cocaine use as a further covariate did not change the results. 
The ADHD-SR sum score was significantly correlated with mean %PPI across conditions in cocaine 
users as well (r=.25, p<.02). To test the influence of ADHD on PPI, cocaine users were divided into 
cocaine users with and without ADHD according to DSM-IV criteria and compared with controls 
(Figure S5). A mixed effects ANCOVA (SOA*group) revealed a significant main effect for group 
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(F(2,153)=6.67, p<.002). Sidak-corrected pairwise comparisons revealed that cocaine users with 
ADHD showed a significantly increased PPI in comparison to controls (p<.001, d=.76). Interestingly, 
in cocaine users with ADHD PPI enhancement was most pronounced in the SOA 30 and 240 
conditions. Cocaine use parameters did not differ between cocaine users with and without ADHD (all 
p>.47), and ADHD-SR sum score was not correlated with cocaine use parameters. Introducing 
cumulative cocaine use as a covariate in the mixed effects ANCOVA (SOA*group) revealed similar 
results (group: F(2,152)=5.57, p<.005). 
When comparing cocaine users stratified for an ADHD diagnosis (yes/no) and craving (high/low) with 
controls (Figure 4), a mixed effects ANCOVA (SOA*group) revealed a significant main effect for 
group (F(4,151)=4.74, p=.001). Controls differed significantly from cocaine users with ADHD and 
high craving (p<.03, d=.78) and cocaine users without ADHD and high craving (p<.03, d=.66). 
Cocaine users without ADHD and low craving displayed normal PPI levels. Cocaine use parameters 
again did not differ between cocaine user groups. Introducing cumulative cocaine use as a covariate 
did not reveal other results. 
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Discussion 
The present study demonstrates that both, RCU and DCU, showed clearly increased PPI levels 
compared to stimulant-naïve controls. Hair toxicologies and comprehensive psychiatric diagnostics 
allowed the analysis of a relatively pure and well-described group of cocaine users with little 
psychiatric comorbidities and without polytoxic drug use. Correlation analyses suggest a positive 
association between amount and duration of cocaine use and PPI. No significant differences between 
groups were found with regard to startle reactivity or habituation measures. Furthermore, PPI was 
significantly augmented in cocaine users with negative urine samples, while users who tested positive 
for cocaine displayed almost normal PPI levels at least in 60 and 240ms SOA conditions. Finally, 
cocaine users with ADHD symptoms and high craving showed the strongest increase in PPI, while 
cocaine users without ADHD but high craving still showed significantly enhanced PPI. 
 
In the sole previous study, Efferen et al.(31) reported a statistical trend towards increased PPI in DCU, 
which was confirmed in the present investigation. Presumably because of the small sample size (10 
cocaine users, 9 controls) and the analysis of only three out of six blocks of stimulus trials the effect 
did not reach significance before (31). In contrast to results obtained in short-term cocaine-withdrawn 
rats, showing no alterations in PPI (29,30), PPI seems to be sensitive to the lasting effects of cocaine 
use in humans and the species-specific results might be ascribed to differences in drug dose, route and 
duration of administration, abstinence period, and pharmacokinetics (55). 
The PPI increase most likely reflects alterations in catecholamine neurotransmission: 
1) As CSPP circuits regulating PPI and reward circuits, shown to be altered in cocaine users, overlap 
in the ventral striatum, changes of the striatal DA system are possible (10,11,22,23). This 
interpretation would be in line with previous studies reporting reduced striatal DA functioning in DCU 
by applying PET imaging (10-13). DA agonists decrease PPI in rodents (23,56) and humans (55,57). 
Furthermore, some DA-antagonistic antipsychotics increase PPI in rats (23,56,58,59) and humans 
(60,61), whereas others like haloperidol have been shown to have no effect or decrease PPI in humans 
(28,62,63). Thus, the role of striatal DA in the modulation the PPI might be more complex than a 
simple linear relationship between striatal DA concentration and PPI expression.  
13    K. H. Preller, et al. 
2) An increase of thalamic NE transporter density has been reported in DCU (16) and growing 
evidence suggests an involvement thalamocortical and ventral forebrain NE transmission in the 
regulation of PPI (25-28,64). Therefore, also dysregulation of NE transmission in CDU as well as 
RCU might contribute to the current results (17). Changes of the NE system would also be in line with 
the present and previous findings of slightly reduced startle magnitudes in cocaine users, because 
pharmacological as well as developmental lesions of the NE system can cause reductions of startle 
reactivity (65-67).  
The finding that PPI was increased exclusively in cocaine users with negative urine samples further 
support the view that reduced catecholamine levels are responsible for this effect. Users with positive 
urine samples have used cocaine recently, which is supposed to enhance DA and NE levels and reduce 
PPI (29,57,68). Furthermore, increased PPI was significantly correlated with amount and duration of 
cocaine use, which suggests that the alterations in PPI might be substance-induced. PPI seems to be 
more sensitive to cumulative use compared to recent drug use patterns, as it did not correlate with 
weekly consumption or hair toxicologies, suggesting that rather long-term changes in catecholamine 
systems are associated with enhanced PPI. However, although correlations between PPI, cocaine use, 
and craving may indicate drug withdrawal-induced PPI augmentation, it cannot be ruled out that 
alterations in PPI and neurotransmitter signaling precede cocaine use and possibly represent a 
vulnerability to develop cocaine addiction.  
 
Replicating earlier studies, PPI was reduced in women in the luteal phase of the ovarian cycle (51,52). 
This was explained by an increase in estrogen during the luteal phase, which results in elevated striatal 
DA release (69). However, as the distribution of women in the luteal and follicular phase did not differ 
between groups and menstrual cycle combined with sex was included as a covariate, it is unlikely that 
PPI differences between cocaine users and controls can be attributed to sex or hormonal changes. 
 
In line with previous studies in humans (31) and rodents (30), startle reactivity and habituation were 
slightly reduced in DCU, but the differences did not reach significance. Though, previous results on 
startle reactivity have been somewhat inconsistent so far. Whereas Efferen et al.(31) reported 
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decreased startle magnitudes in early abstinent cocaine users, Corcoran et al.(32) referred reduced 
startle reactivity not until 40 days of abstinence. In our study, duration of self-reported cocaine 
abstinence was not correlated with startle reactivity (p=.80). Though, further studies are needed to 
disclose the influence of abstinence duration on startle reactivity and PPI in cocaine users. 
 
Additionally, we examined the influence of craving and ADHD on PPI, as craving has been associated 
with dysregulated striatal DA and NE levels (12,17,18,36). Furthermore, dysfunction of NE and DA 
neurotransmission have been proposed to underlie the pathophysiology in ADHD (34,35,70). ADHD 
symptomatology and craving both increased PPI in cocaine users compared to controls, even if 
amount and duration of cocaine use were controlled. Low craving scores were associated with widely 
normal PPI, independent of ADHD diagnosis. Previous studies reported no significant effect of 
ADHD on PPI in adults (71,72). However, two studies reported slight but non-significant increases of 
PPI in untreated (n=13) or treatment-withdrawn (n=22) adults with ADHD (72,73), while stimulant-
treated ADHD patients (n=10) displayed somewhat lower PPI levels (72). Perhaps, these studies were 
underpowered and therefore did not reveal an increase of PPI, even though the study of Feifel et 
al.(71) did not find PPI differences between unmedicated adult ADHD patients (n=20) and controls 
(n=17). Maybe the PPI-increasing influence of ADHD symptoms shown here only arises from an 
interaction of cocaine use and underlying ADHD pathophysiology. Taken together, our results might 
explain why ADHD patients seem to be more vulnerable for addiction than healthy subjects (74) 
because our results indicate that cocaine using ADHD individuals experience stronger craving 
symptoms (reflected by maximum PPI increase), possibly due to greater changes catecholamine 
systems. Additionally, given that we studied only unmedicated cocaine users, cocaine might also be 
utilized as a self-medication in our users showing ADHD symptoms (74). The need for self-
medication might reflect a dysfunctional catecholamine system, which in turn could be more 
vulnerable for neurochemical plasticity induced by cocaine. 
 
As cocaine users tested in this study showed minimal to moderate co-use of MDMA and cannabis, 
their influence on PPI was further analyzed. In previous studies, cannabis use did not show significant 
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effects on PPI at least passive attention paradigms just as used here (40,75,76). However, controls with 
positive cannabis urine toxicology showed a slight even though non-significant increase of PPI, which 
is in line with several animal studies observing that acute administration of cannabinoid-1 receptor 
agonists increase PPI (77,78). However, controls and cocaine users with negative cannabis urine 
samples still significantly differed, indicating that our result can not be explained by cannabis co-use 
(Figure 2). Moreover, we have previously shown that MDMA users also display elevated PPI levels 
(40) but here we did not find an additional increase of PPI in cocaine users with a limited co-use of 
MDMA. This difference may be explained by either a ceiling effect or by the exclusion of cocaine 
users with a regular or high use of MDMA in the present study. Given that also MDMA-naïve cocaine 
users displayed enhanced PPI levels (Figure S7) our results can not be attributed to the MDMA co-use 
of some users. 
 
The study has some limitations: First, we have no objective measure of the duration of abstinence 
beyond urine toxicologies but have to rely on self-reports. Thus, we were unable to investigate the true 
effect of abstinence duration on startle parameters. However, it would have been nearly impossible to 
control for abstinence in our ambulant and voluntary study setting. Second, although this is one of the 
first investigations employing hair toxicologies in an electrophysiological study with cocaine users we 
can only rely on self-reports for illegal drug use prior to 3-6 months (depending on hair length), which 
is nevertheless an inevitable constraint in all studies with illegal drug users (79).  
 
In sum, RCU and DCU showed an increase of PPI that was correlated with duration and amount of 
cocaine use, as well as the strength of cocaine craving. These data suggest that already recreational use 
of cocaine is associated with altered catecholamine signaling, which is in line with our previous 
finding of altered blue-yellow color vision in RCU (19). Moreover, the elevation of PPI was most 
pronounced in subjects with clinically relevant ADHD symptoms and high craving. PPI might 
therefore provide a non-invasive, simple, and cheap measure to objectively capture acute stimulant 
craving symptoms. Finally, our data imply that ADHD might be a critical risk factor for cocaine-
induced changes of catecholamine systems. 
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Figure legends 
 
Fig. 1 – Mean percent prepulse inhibition (%PPI) in recreational (n=64) and dependent cocaine users 
(n=29), and healthy control participants (n=66). Recreational and dependent cocaine users show 
significantly increased PPI. Error bars refer to SEM. * indicates significant difference between groups 
(p<0.05). 
 
Fig. 2: Mean %PPI in control participants with positive (n=12) and negative (n=54) urine samples for 
cannabis, and cocaine users with positive (n=34) and negative (n=59) urine samples for cannabis. 
Error bars refer to SEM. *indicates significant difference between groups (Sidak-post hoc test: 
p<0.05). 
 
Figure 3: Mean %PPI across SOA conditions in non-smoking controls (controls, ns) (n=16) smoking 
controls (controls, s) (n=50), non-smoking cocaine users (cocaine users, ns) (n=19), and smoking 
cocaine users (cocaine users, s) (n=74). Error bars refer to SEM. *indicates significant difference 
between groups (Sidak-post hoc test: p<0.05). 
 
Fig. 4 – Mean percent prepulse inhibition (%PPI) in cocaine users with ADHD and high craving 
(n=10), cocaine users with ADHD and low craving (n=12), cocaine users without ADHD and high 
craving (n=31), cocaine users with ADHD and low craving (n=40), and controls (n=66). High craving 
cocaine users with and without ADHD show significantly augmented PPI, while cocaine users without 
craving and ADHD display widely normal PPI levels. Error bars refer to SEM. *indicates significant 
difference between groups (Sidak post hoc test: p<0.05). 
 
22              K. H. Preller, et al. 
Table 1 Demographic data (means and standard deviation) 
 Control group 
(n=66) 
Recreational cocaine users 
(RCU, n=64) 
Dependent cocaine users 
(DCU, n=29) Value df/dferr p 
       
Male/ female follicular/female 
luteal phase (n) 
46/15/5 46/9/9 25/3/1 χ2 =5.94 b 4 0.20 
Age (years) 31.11 (9.40) 28.11 (6.24) 36.28 (11.45)*° F = 8.80c 2/156 <0.001 
Years of education  10.67 (1.87) 10.42 (1.91) 9.57 (1.24)* F = 3.89c 2/156 0.02 
Verbal IQ 106.09 (11.20) 102.44 (9.00) 102.10 (10.97) F = 2.57c 2/156 0.08 
Smoker/nonsmoker (n) 50/16 51/13 23/6 χ2 = 0.33b 2 0.85 
FTND sum score (0-10)a 2.24 (2.11) 3.29 (2.10)* 4.87 (2.53)**° F = 11.56c 2/122 <0.001 
Craving for cocaine (0-70) - 18.92 (9.01) 18.97 (10.55) t = 0.02d 91 0.98 
ADHD-SR sum score (0-22) 7.74 (4.75) 13.39 (9.11)** 15.50 (9.16)** F = 13.88c 2/156 <0.001 
BDI sum score (0-63) 4.42 (4.38) 7.70 (6.76)** 10.34 (7.58)** F = 10.73c 2/156 <0.001 
Hair color (n) 
(black/brown/blonde/dyed) 
4/54/3/2 6/64/3/1 6/21/2/0 χ2 = 5.94b 6 0.43 
Significant p values are shown in bold. Sex and smoking in frequency data. FTND, Fagerstrom Test of Nicotine Dependence; ADHD, ADHD self rating scale; BDI, Beck 
Depression Inventory. 
aFTND measured in smokers only. bχ2 test (all groups) for frequency data. cANOVA (all groups). dIndependent t-test (cocaine users only) 
*indicates significant post-hoc test (Sidak) vs. control group: p<0.05 
**indicates significant post-hoc test (Sidak) vs. control group: p<0.01 
°indicates significant post-hoc test (Sidak) vs. recreational cocaine users group: p<0.05 
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Table 2 Pattern and amount of drug use: Results of the Psychotropic Drug Interview, urine toxicology, and hair samples  
 Control group (n=66) 
Recreational cocaine users 
(RCU, n=64) 
Dependent cocaine users 
(DCU, n=29) Value
a df/dferr p 
Cocaine       
  times per weekb - 1.11 (1.08) 2.85 (2.66) F = 20.14 1/91 <0.001 
  grams/weekb - 1.18 (1.46) 8.32 (16.15) F = 12.48 1/91 <0.001 
  years of use - 6.08 (3.93) 10.35 (6.91) F = 14.30 1/91 <0.001 
  maximum dose (24h) - 3.27 (2.37) 10.08 (8.49) F = 35.51 1/91 <0.001 
  last consumption (days) - 24.70 (35.99) 28.39 (38.19) F = 0.19 1/91 0.66 
  cumulative dose (grams) - 500.61 (734.45) 7211.70 (10503.26) F = 26.19 1/91 <0.001 
  urine toxicology (pos/neg) - 13/51 13/16 χ2 = 5.73 1 0.02 
  hair sample (pg/mg)       
    cocaine - 2780.94 (4695.09) 19967.93 (33082.52) F = 16.75 1/91 <0.001 
    benzoylecgonine - 565.51 (932.77) 4313.62 (7531.84) F = 15.53 1/91 <0.001 
    ethylcocaine - 271.83 (312.28) 1879.31 (3721.96) F = 11.91 1/91 <0.001 
    norcocaine - 63.45 (101.19) 501.64 (739.20) F = 21.87 1/91 <0.001 
        
MDMA       
  tablets/weekb - 0.09 (0.27) 0.42 (1.86) F = 1.91 1/91 0.17 
  years of use 1.60 (11.31) 2.51 (3.81) 2.97 (5.35) F = 0.37 2/156 0.69 
  last consumption (days)c - 66.33 (83.34) (n=20) 77.20 (45.91) (n=8) F = 0.12 1/26 0.73 
  cumulative dose (tablets) 0.61 (1.86) 37.70 (92.94) 139.10 (400.50)**° F = 6.00 2/156 <0.01 
  hair sample (pg/mg) 2.74 (16.24) 627.24 (1660.04)** 240.86 (663.88) F = 5.15 2/153 <0.01 
        
Cannabis       
  grams/weekb 0.53 (1.47) 0.87 (2.01) 1.85 (4.84) F = 2.63 2/156 0.08 
  years of use 5.68 (7.32) 7.56 (5.65) 10.35 (10.66)* F = 4.02 2/156 0.02 
  last consumption (days)c 37.35 (52.23) (n=32) 20.67 (30.84) (n=43) 24.94 (30.72) (n=17) F = 1.66 2/89 0.20 
  cumulative dose (grams) 426.73 (903.46) 1082.74 (1780.72) 4491.36 (7478.60)**°° F  = 14.84 2/156 <0.001 
  urine toxicology (pos/neg) 12/54 23/40 11/18 χ2 = 6.58 2 0.04 
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Table 2 Pattern and amount of drug use: Results of the Psychotropic Drug Interview, urine toxicology, and hair samples (continued) 
 Control group 
(n=66) 
Recreational cocaine users 
(RCU, n=64) 
Dependent cocaine users 
(DCU, n=29) Value
a df/dferr p 
Amphetamine       
  grams/weekb - 0.08 (0.21)** 0.01 (0.04) F = 2.58 1/92 0.11 
  years of use 0.01 (0.06) 1.64 (2.99)** 1.48 (3.23)* F = 8.87 2/156 <0.001 
  last consumption (days)c - 63.10 (52.08) (n=24) 93.06 (74.12) (n=5) F = 1.19 1/27 0.29 
  cumulative dose (grams) 0.17 (1.44) 22.58 (59.01)* 16.70 (61.01) F = 4.10 2/156 0.02 
  hair sample (pg/mg) 0.9 (7.56) 75.47 (259.52) 44.31 (158.97) F = 2.73 2/153 0.07 
        
GHB       
  cumulative dose (pipettes) - 1.79 (9.77) 1.14 (2.89) F = 0.12 1/91 0.73 
        
Hallucinogenes        
  cumulative dose (times) 1.80 (7.13) 6.78 (15.14) 8.07 (15.37) F = 3.69 2/156 0.03 
        
Alcohol       
  grams/weekb 118.83 (126.58) 174.96 (118.65) 196.09 (286.64) F = 2.97 2/156 0.05 
  years of use 13.83 (9.61) 10.84 (5.08) 14.73 (9.80) F = 3.22 2/156 0.04 
        
Nicotine       
  cigarettes per day (CPD)b 9.03 (9.49) 11.96 (8.33) 15.60 (14.20)* F = 4.43 2/156 0.01 
  years of use 9.52 (9.68) 9.53 (6.34) 15.78 (11.33)**°° F = 5.91 2/156 <0.01 
Means and standard deviations in parenthesis. Significant p values are shown in bold. Consumption per week, duration of use, and cumulative dose are averaged within the total 
group.  
aANOVA or χ2 test for frequency data  
baverage use during the last six months 
cLast consumption is averaged only for persons who used the drug in the last 6 months. In this case, sample size (n) is shown.  
*indicates significant post-hoc test (Sidak) vs. control group: p<0.05 
**indicates significant post-hoc test (Sidak) vs. control group: p<0.01 
°indicates significant post-hoc test (Sidak) vs. recreational cocaine users group: p<0.05 
°° indicates significant post-hoc test (Sidak) vs. recreational cocaine users group: p<0.01
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Table 3 Startle reactivity, mean %PPI and habituation 
  Control group 
(n=66) 
Recreational cocaine users 
(RCU, n=64) 
Dependent cocaine users 
(DCU, n=29) Value
a df/dferr p 
PA first block (μV) 121.52 (103.54) 120.72 (68.46) 91.19 (61.15) F = 0.70 2/153 0.50 
PA mean across blocks (μV) 82.00 (61.23) 76.74 (51.13) 58.57 (45.29) F = 0.88 2/153 0.42 
PPA mean (μV) 6.60 (6.72) 6.40 (5.39) 5.28 (3.12) F = 0.31 2/153 0.74 
Baseline (μV) 3.07 (1.39) 2.96 (1.30) 3.04 (1.34) F = 0.63 2/153 0.53 
%PPI mean across conditions 49.68 (23.02) 57.83 (20.88)* 64.15 (15.11)* F = 4.58 2/153 0.01 
Habituation       
   %habituation block 2-3 20.05 (37.85) 23.17 (31.99) 12.23 (52.26) F = 0.83 2/153 0.44 
   %habituation block 2-4 25.68 (41.41) 26.91 (47.11) 32.10 (36.62) F = 0.32 2/153 0.72 
   coefficient b -21.68 (28.64) -21.34 (16.37) -19.06 (14.48) F = 0.12 2/153 0.89 
Means and standard deviations in parenthesis. Significant p values are shown in bold. 
PA, pulse alone trials; PPA, prepulse alone trial; PPI, prepulse inhibition 
aANCOVA including all groups (sex, age and smoking status as covariates) 
*indicates significant post-hoc test (Sidak) vs. control group: p<0.05 
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Supplemental Methods 
Recruitment and Selection Details 
 Participants were recruited in the Zurich area by means of advertisements in local newspapers, 
drug prevention and treatment centers, psychiatric hospitals, and internet platforms. Eight-hundred-
four potential participants completed an initial telephone screening, whereof 240 subjects participated 
in the study. Forty-six participants had to be excluded afterwards because of hair analyses revealing 
illegal drug use not declared in the interviews (e.g., opioids, excessive 3,4-methylenedioxy-N-
methylamphetamine (MDMA) use or polydrug use) or lack of cocaine use. Furthermore, the startle 
data of 19 participants (11 controls, 8 cocaine users) could not be analyzed because of technical 
problems/equipment malfunction during the test session. Further 16 participants were excluded due to 
matching reasons (age, IQ, education, and smoking) between groups (9 controls, 1 cocaine user), 
startle non-responding (2 controls), and hearing problems (4 cocaine users). Therefore, 159 datasets 
were included in the analysis. Hair samples were provided by 156 subjects, as hair analysis was not 
possible by reason of an insufficient amount of hair for three control subjects. Women provided 
information on the days since their last menstruation. Women in the first 14 days of the cycle were 
considered in the follicular phase, in the last 14 days in the luteal phase. 
 
Urine and Hair Toxicologies 
 Urine toxicology analyses comprised the compounds/substances: tetrahydrocannabinol, 
cocaine, amphetamines, benzodiazepines, opioids, and methadone and were assessed by a semi-
quantitative enzyme multiplied immunoassay method using a Dimension RXL Max (Siemens, 
Erlangen, Germany). 
 To characterize drug use over the last six months objectively, hair samples were collected and 
analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS). If participants’ hair 
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was long enough, one sample of six cm hair (from the scalp) was taken and subsequently divided into 
two subsamples of three cm length. The following compounds were assessed: cocaine, 
benzoylecgonine, ethylcocaine, norcocaine, amphetamine, methamphetamine, MDMA, 3,4-
methylenedioxy-N-ethylamphetamine (MDEA), 3,4-methylenedioxyamphetamine (MDA), morphine, 
codeine, methadone EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; primary methadone 
metabolite), tramadol, and methylphenidate. 
 For our routine protocol for drugs of abuse analysis, a three step washing procedure with water 
(2 minutes shaking, 15 ml), acetone (2 min., 10 ml) and finally hexane (2 min., 10 ml) of hair was 
performed. Then the hair samples were dried at ambient temperatures, cut into small snippets and 
extracted in two steps, first with methanol (5 ml, 16 hours, ultrasonication) and a second step with 3 
ml MeOH acidified with 50 µL hydrochloric acid 33% (3 hours, ultrasonication). The extracts were 
dried and the residue reconstituted with 50 µL MeOH and 500 µL 0.2 mM ammonium formate 
(analytical grade) in water. As internal standards deuterated standards of the following compounds 
were used, added as mixture of the following compounds: cocaine-d3, benzoylecgonine-d3, 
ethylcocaine-d3, morphine-d3, MAM-d3, codeine-d3, dihydrocodeine-d3, amphetamine-d6, 
methamphetamine-d9, MDMA-d5, MDEA-d6, MDA-d5, methadone-d9, EDDP-d3, methylphenidate-
d9, tramadol-d3, oxycodone-d3, and ephedrine-d3. All deuterated standards were from ReseaChem 
(Burgdorf, Switzerland), the solvents for washing and extraction were of analysis grade and obtained 
from Merck (Darmstadt, Germany); LC-solvents were of high-performance LC grade and were 
obtained from Sigma Aldrich (Buchs, Switzerland). 
 The LC-MS/MS apparatus was an ABSciex QTrap 3200 (Analyst software Version 1.5, Turbo 
V ion source operated in the ESI mode, gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray 
voltage, 3500V; ion source temperature, 450°C; curtain gas, nitrogen (20 psi) collision gas, medium), 
with a Shimadzu Prominence LC-system (Shimadzu CBM 20 A controller, two Shimadzu LC 20 AD 
pumps including a degasser, a Shimadzu SIL 20 AC autosampler and a Shimadzu CTO 20 AC column 
oven, Shimadzu, Duisburg, Germany). Gradient elution was performed on a separation column 
(Synergi 4µ POLAR-RP 80A, 150x2.0 with a POLAR-RP 4x2.0 Security Guard Cartridge, 
(Phenomenex, Aschaffenburg, Germany). The mobile phase consisted of 1 mM ammonium formate 
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buffer adjusted to pH 3.5 with formic acid (eluent A) and acetonitrile containing 1 mM ammonium 
formate and 1 mM formic acid (eluent B). The analysis was performed in multiple reaction monitoring 
mode with two transitions per analyte and one transition for each deuterated internal standard, 
respectively. 
 
Startle Response Measurement 
 Electromyographic (EMG) recording was performed in a sound-attenuated room. All 
participants underwent a short hearing test before the test session to ensure hearing within normal 
limits. Participants were informed that they would hear broadband noise and bursts over the 
headphones. They were asked to sit comfortably, stay awake, and keep their eyes open. The eye-blink 
component of the acoustic startle response was measured by an EMG startle system (EMG-SR-Lab; 
San Diego Instruments, Inc., San Diego, CA). EMG activity was measured from the right orbicularis 
oculi muscle using two silver/silver chloride electrodes. A reference electrode was placed on the 
glabella. All electrode resistances were less than 10 kΩ. The system recorded continuously over the 
whole session with a sampling rate of 4096 Hz. Acoustic startle stimuli were presented binaurally 
using headphones (TDH-39-P; Maico). The test session started with a 2-min acclimation period of 70 
dB background broadband noise that was continued throughout the session. Startle stimuli comprised 
of noise bursts at an 115 dB sound pressure level with duration of 40 ms, separated by variable 
intertrial intervals (range: 9-14 seconds, mean: 12 seconds). After an initial pulse-alone trial (PA) the 
session included a total of 64 trials (56 active and 8 no-stimulation trials) and lasted 13 minutes. 
Thirty-two pulse trials were preceded by a 20 ms prepulse with an intensity of 86 dB and a stimulus 
onset asynchrony (SOA) of 30, 60, 120, and 240 ms, resulting in four prepulse (PP) trial conditions. 
Rise and fall times of all stimuli were less than 1 ms. Four startle stimuli were presented at the 
beginning (block 1) and four startle stimuli at the end (block 4) to assess habituation. Eight no-
stimulation (NS) trials and eight prepulse-alone (PPA) trials were recorded to assess baseline EMG 
activity. PPA trials, NS trials and each of 4 prepulse trial conditions were presented in a 
pseudorandomized order in blocks 2 and 3. 
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Supplemental Results 
Cannabis and MDMA 
 Groups of high and low cannabis and MDMA users were created by median split of 
cumulative use. Cannabis use (cumulative use, duration of use, grams per week) was not correlated 
with %PPI in the cocaine user group. An analysis of covariance comparing the % prepulse inhibition 
(%PPI) mean across conditions between cocaine users with no (n = 9), low (n = 41), and high (n = 41) 
cannabis use did not reveal a significant difference (F(2,85) = .72, p = .49) (Figure S6). Introducing 
cumulative cannabis use as a covariate in the main PPI analysis did not alter the results.  
 MDMA use measures (cumulative use, duration of use, tablets per week) were also not 
correlated with %PPI in the cocaine user group (all p > .31). The comparison of %PPI mean across 
conditions between cocaine users with no (n = 26), low (n = 37), and high (n = 30) MDMA use did not 
reveal a significant difference (F(2,87) = .20, p = .82) (Figure S7). Moreover, introducing cumulative 
MDMA use as a covariate in the main PPI analysis did not change the results.  
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Figure S1. Habituation curve diagrammed as mean amplitude of pulse-alone (PA) trials in four 
blocks, corrected for startle reactivity in the first block (means ± SEM) for recreational (n = 64) and 
dependent cocaine users (n = 29), and healthy control participants (n = 66). Each block contains four 
116-db PA trials. 
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Figure S2. Cumulative lifetime cocaine use in grams (ln-transformed) and mean % prepulse inhibition (%PPI) across all conditions in cocaine users (r = .23, p < 
.05) (A) and duration of cocaine use in years and mean %PPI across all conditions in cocaine users (r = .22, p < .05) (B). The exclusion of the outlying value 
reporting 30 years of cocaine use did not change the correlation between duration of cocaine use and %PPI (r = .23, p < .03). 
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Figure S3. Mean % prepulse inhibition (%PPI) in cocaine users with positive (n = 26) and negative (n 
= 67) urine samples for cocaine, and healthy control participants (n = 66). Error bars refer to SEM. 
*indicates significant difference between groups (Sidak-post hoc test: p < .05). SOA, stimulus onset 
asynchrony. 
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Figure S4. Mean % prepulse inhibition (%PPI) in low (n = 52) and high (n = 41) craving cocaine 
users and controls (n = 66). Cocaine users with high craving show increased PPI. Error bars refer to 
SEM. *indicates significant difference between groups (Sidak-post hoc test: p < .05). SOA, stimulus 
onset asynchrony. 
 
Preller et al. 
9 
 
 
Figure S5. Mean % prepulse inhibition (%PPI) in cocaine users with attention-deficit/hyperactivity 
disorder (ADHD) (n = 22) and without ADHD (n = 72), and healthy control participants (n = 66). 
Error bars refer to SEM. *indicates significant difference between groups (Sidak-post hoc test: p < 
.05). SOA, stimulus onset asynchrony. 
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Figure S6. Mean % prepulse inhibition (%PPI) across conditions in cocaine users with no (n = 9), low 
(n = 41) and high (n = 41) cumulative cannabis use. The red line represents the PPI level of the 
controls without cannabis use for comparison. Error bars refer to SEM.  
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Figure S7: Mean % prepulse inhibition (%PPI) across conditions in cocaine users with no (n = 26), 
low (n = 37) and high (n = 30) cumulative MDMA use. The red line represents the PPI level of the 
controls for comparison. Error bars refer to SEM.  
 
 
